1. O’Dwyer, PJ, Leyland-Jones, B, Alonso, MT, et al. Etoposide (VP-16-213): current status of an active anticancer drug. N Engl J Med 1985; 312: 692–700.
Google Scholar | Crossref | Medline | ISI2. Henwood, JM, Brogden, RN. Etoposide: a review of its pharmacokinetic and pharmacodynamic properties, and therapeutic potential in combination chemotherapy on cancer. Drugs 1990; 39: 438–490.
Google Scholar | Crossref | Medline | ISI3. Hartmann, JT, Lipp, HP. Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II – mechanisms of action, pharmacokinetics and toxicity profile. Drug Saf 2006; 29: 209–230.
Google Scholar | Crossref | Medline4. Witterland, AHI, Koks, CHW, Beijnen, JH. Etoposide phosphate, the water soluble prodrug of etoposide. Pharm World Sci 1996; 18: 163–170.
Google Scholar | Crossref | Medline5. Williams, SD, Birch, R, Einhorn, LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin and either vinblastine or etoposide. N Engl J Med 1987; 316: 1435–1440.
Google Scholar | Crossref | Medline | ISI6. Donohue, JP, Thornhill, JA, Foster, RS, et al. The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the indiana university experience (1965 to 1989). J Urol 1995; 153: 85–89.
Google Scholar | Crossref | Medline | ISI7. Cheriyan, SK, Nicholson, M, Aydin, AM, et al. Current management and management controversies in early- and immediate-stage of nonseminoma germ cell tumours. Transl Androl Urol 2020; 9: S45–S55.
Google Scholar | Crossref | Medline8. O’Dwyer, PJ, Weiss, RB. Hypersensitivity reactions induced by etoposide. Cancer Treat Rep 1984; 68: 959–961.
Google Scholar | Medline9. Sutherland, CM, Loufti, A. Unusual reaction to VP-16-213 and avoidance by prolonged infusion. Cancer Treat Rep 1982; 66: 409.
Google Scholar10. Ogle, KM, Kennedy, BJ. Hypersensitivity reactions to etoposide: a case report and review of the literature. Am J Clin Oncol 1988; 11: 663–665.
Google Scholar | Crossref | Medline | ISI11. Hudson, MM, Weinstein, HJ, Donaldson, SS, et al. Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin's Disease. J Clin Oncol 1993; 11: 1080–1084.
Google Scholar | Crossref | Medline | ISI12. De Souza, P, Friedlander, M, Wilde, C, et al. Hypersensitivity reactions to etoposide. Am J Clin Oncol 1994; 17: 387–389.
Google Scholar | Crossref | Medline | ISI13. Siderov, J, Zalcberg, J. Safe administration of oral etoposide after hypersensitivity reaction to intravenous etoposide. Anti-Cancer Drugs 1994; 5: 602–603.
Google Scholar | Crossref | Medline14. Bernstein, BJ, Troner, MB. Successful rechallenge with etoposide phosphate after an acute hypersensitivity reaction to etoposide. Pharmacother 1999; 19: 989–991.
Google Scholar | Crossref | Medline | ISI15. Siderov, J, Prasad, P, De Boer, R, et al. Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide. Br J Cancer 2002; 86: 12–13.
Google Scholar | Crossref | Medline | ISI16. Collier, K, Schink, C, Young, AM, et al. Successful treatment with etoposide phosphate in patients with previous etoposide hypersensitivity. J Oncol Pharm Pract 2008; 14: 51–55.
Google Scholar | SAGE Journals17. Starks, D, Prinz, D, Armstrong, A, et al. Management of a type I hypersensitivity reaction to IV etoposide in a woman with a yolk sac tumour: a case report. Case Rep Obstet Gynecol 2011; 2011: 837160.
Google Scholar | Medline18. Stockton, WM, Nguyen, T, Zhang, L, et al. Etoposide and etoposide phosphate hypersensitivity in children: incidence, risk factors and preventative strategies. J Oncol Pharm Pract 2020; 26: 397–405.
Google Scholar | SAGE Journals | ISI19. Lindsay, H, Gaynon, P. Anaphylactic reaction to etoposide phosphate. Pediatr Blood Cancer 2012; 59: 765.
Google Scholar | Crossref | Medline | ISI20. Sambasivan, K, Mahmoud, S, Kokache, A, et al. Hypersensitivity reactions to etoposide phosphate. J Oncol Pharm Pract 2014; 20: 158–160.
Google Scholar | SAGE Journals | ISI21. Cotteret, C, Rousseau, J, Zribi, K, et al. Severe hypersensitivity reaction to etoposide phosphate: a case report. Clin Case Rep 2020; 8: 1821–1823.
Google Scholar | Crossref | Medline22. Leguay, Z, Pellier, I, Le Louet, H, et al. Successful treatment with etoposide base after an acute hypersensitivity reaction to etoposide phosphate. Pediatr Blood Cancer 2016; 63: 571.
Google Scholar | Crossref | Medline23. Schwartz, LS, Navali, RM. Safety of polysorbate 80 in the oncology setting. Adv Ther 2018; 35: 754–767.
Google Scholar | Crossref | Medline24. Michelson, E . Anaphylactic reactions to dextrans. N Engl J Med 1968; 278: 552.
Google Scholar | Crossref | Medline25. Zinderman, CE, Landow, L, Wise, RP. Anaphylactoid reactions to dextran 40 and 70: reports to the United States food and drug administration, 1969–2004. J Vasc Surg 2006; 43: 1004–1009.
Google Scholar | Crossref | Medline26. Lam, MSH . The need for routine bleomycin test dosing in the 21st century. Ann Pharmacother 2005; 39: 1897–1902.
Google Scholar | SAGE Journals | ISI27. Makrilia, N, Syrigou, E, Kaklamanos, I, et al. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met-Based Drugs 2010; 2010: 207084.
Google Scholar | Medline28. Giavina-Bianchi, P, Patil, SU, Banerji, A. Immediate hypersensitivity reaction to chemotherapeutic agents. J Allergy Clin Immunol Pract 2017; 5: 593–599.
Google Scholar | Crossref | Medline29. Naranjo, CA, Busto, U, Sellers, EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–245.
Google Scholar | Crossref | Medline | ISI